In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co-Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Rick Pierce, CEO of Decoy Therapeutics (NASDAQ: DCOY). The conversation explores Decoy’s innovative business model for developing peptide‑conjugate antivirals designed to target multiple respiratory viruses. Pierce explains how Decoy is navigating the modern era of drug development with a cost‑effective, highly efficient strategy that positions the company as a disruptive force in biotech. Central to this approach is Decoy’ proprietary peptide‑synthesis technology and rapid design‑build‑test cycle, powered by machine learning. He also underscores the importance of Decoy’s strategic partnerships with the Gates Foundation, Google, and NVIDIA in advancing its platform and accelerating development.

In this episode of the WTR Healthcare Happenings podcast, Tim Gerdeman, Vice Chair, Co‑Founder, and CMO of Water Tower Research, and Robert Sassoon, WTR’s Healthcare Research Analyst, speak with Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma (NASDAQ: MDCX). Dr. Bokhari outlines Medicus Pharma’s distinctive strategy of acquiring de‑risked, mid‑stage therapeutic assets and advancing them through Phase 2 development to attract major pharmaceutical partners. The discussion centers on the company’s two lead programs- Skinjet, a novel microneedle patch offering a non‑invasive alternative to surgery for non‑melanoma skin cancer, and Teverelix, a next‑generation therapy targeting prostate cancer and urinary retention. Dr. Bokhari elaborates on the company's strategic integration of generative AI through a partnership with Reliant AI to optimize clinical trial efficiency and outlines Medicus Pharma’s financial strategy, focusing on upcoming data readouts and non-dilutive capital through out-licensing opportunities.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and WTR’s Robert Sassoon speak with Dr. Lior Shaltiel, CEO of NuroExone Biologic (OTCQB: NRXBF/TSXV: NRX), an early-stage regenerative therapy developer. The conversation centers on NurExone’ lead product, ExoPTEN, a therapeutic platform that combines exosomes with siRNA to promote nerve regeneration in multi-billion dollar markets like spinal cord and optic nerve injury. Dr. Shaltiel outlines the company’s strong preclinical evidence, its de-risked characteristics bolstered by Orphan Drug Designation in both the US and Europe, and the company's multi-layered patent strategy. He also highlights NuRexone' unique US-based manufacturing model designed to generate revenue within the next year as they move toward clinical trials.

In this episode of the WTR Healthcare Happenings Podcast, Tim Gerdeman and Robert Sassoon speak with Jim Martin, Co‑CEO and CFO of Cocrystal Pharma (NASDAQ: COCP). Martin explains the company’s Nobel Laureate‑developed drug discovery platform, which uses high-resolution crystallography to target viral regions resistant to mutation, enabling broad‑spectrum antivirals. The discussion highlights Cocrystal’s lead candidate, CDI‑988, a dual‑indication antiviral for coronaviruses and noroviruses, with a particular focus on advancing the norovirus program due to high global unmet need. Martin outlines the ongoing human challenge norovirus study at Emory University, CDI‑988’s potential as therapy and prophylactic, and growing U.S. government and military interest. The episode also highlights the company' upcoming milestones, including mid‑2026 top-line data for the CDI-988 human challenge study, and an overview of its broader pipeline, including influenza A and B programs.

Best,

In this episode of the WTR Healthcare Happenings Podcast, host Tim Gerdeman and healthcare analyst Robert Sassoon are joined by Dr. Jim Gilligan, President and Chief Science Officer of Entropy Neurodynamics (ASX: ENP), formerly Tryptamine Therapeutics. Dr. Gilligan explains the motivation behind the company’s rebrand and its decision to prioritize three core therapeutic targets: Binge Eating Disorder, Fibromyalgia, and Irritable Bowel Syndrome/abdominal pain. Although Entropy has reported positive Phase 2a results using oral psilocybin across these indications, Dr. Gilligan outlines why the company is shifting its strategy toward developing proprietary IV‑delivered psilocin formulations combined with psychotherapy, beginning with binge eating disorder. The discussion also covers Entropy’s work on real‑time EEG and brain entropy as a potential biomarker, the company’s financing, regulatory roadmap, and longer‑term expansion opportunities in areas such as PTSD.

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman sits down with WTR Healthcare analyst Robert Sassoon to discuss his Initiation of Coverage Report on Anixa Biosciences. Their conversation explores Anixa’s two clinical‑stage programs—one, an innovative CAR‑T cell therapy for terminal ovarian cancer patients, and the other, a breast cancer vaccine designed for both treatment and prevention. They review Phase 1 results, upcoming 2026 milestones, and how Anixa differentiates itself through both its scientific platforms and disciplined financial management.

In this special Flashcast episode of the WTR Healthcare Happenings podcast, Tim Gerdeman and WTR Healthcare analyst Robert Sassoon break down why more than 90% of biotech companies listed on a U.S. exchange choose NASDAQ over the NYSE.

In this episode of WTR Healthcare Happenings, host Tim Gerdeman and analyst Robert Sassoon speak with Eric Poma PhD, CEO of Calidi Biotherapeutics Inc (NYSE American: CLDI). The discussion focuses on how Calidi is solving the "delivery problem" in cancer treatment, and specifically how to transport cancer-killing oncolytic viruses systemically through the bloodstream without the body’s immune system neutralizing them before they reach the tumor.